Tumor-Infiltrating Lymphocytes in the Checkpoint Inhibitor Era

Gerald P. Linette,Beatriz M. Carreno

DOI: https://doi.org/10.1007/s11899-019-00523-x

2019-06-11

Current Hematologic Malignancy Reports

Abstract:<h3 class="Heading">Purpose of Review</h3><p class="Para">Checkpoint inhibitors block co-inhibitory signals which serves to promote T cell activation/reinvigoration in the periphery and tumor microenvironment. A brief historical background as well as a summary of key observations related to the composition and prognostic value of tumor-infiltrating lymphocytes (TILs) is discussed.</p><h3 class="Heading">Recent Findings</h3><p class="Para">Solid tumor patients that respond to checkpoint inhibitors have greater CD8+ T cell densities (at the tumor margin) associated with a gene inflammation signature and high tumor mutational burden. The precise specificity of effector (CD8+ T cell) TIL remains poorly defined and this deficiency represents a major challenge for the field of cancer immunology.</p><h3 class="Heading">Summary</h3><p class="Para">High mutational burden cancers such as melanoma provides compelling evidence that missense mutations create neoantigens which can serve as target antigens for the immune system. Emerging evidence suggests that neoantigen-specific TILs are the major effector cells that mediate tumor regression due to checkpoint inhibition.</p>

oncology,hematology